4.5 Article

Small-Molecule Inhibitors That Target Protein-Protein Interactions in the RAD51 Family of Recombinases

期刊

CHEMMEDCHEM
卷 10, 期 2, 页码 296-303

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201402428

关键词

biophysics; BRCA2; homologous recombination; inhibitors; protein-protein interactions; RAD51

资金

  1. Wellcome Trust [GR091058/Z/09/Z, GR080083/Z/06]
  2. EPSRC [EP/K039520/1] Funding Source: UKRI
  3. MRC [MC_UU_12022/8, MC_UU_12022/1, G1001521] Funding Source: UKRI
  4. Engineering and Physical Sciences Research Council [EP/K039520/1] Funding Source: researchfish
  5. Medical Research Council [MC_UU_12022/1, G1001521, MC_UU_12022/8] Funding Source: researchfish

向作者/读者索取更多资源

The development of small molecules that inhibit protein-protein interactions continues to be a challenge in chemical biology and drug discovery. Herein we report the development of indole-based fragments that bind in a shallow surface pocket of a humanised surrogate of RAD51. RAD51 is an ATP-dependent recombinase that plays a key role in the repair of double-strand DNA breaks. It both self-associates, forming filament structures with DNA, and interacts with the BRCA2 protein through a common FxxA tetrapeptide motif. We elaborated previously identified fragment hits that target the FxxA motif site and developed small-molecule inhibitors that are approximately 500-fold more potent than the initial fragments. The lead compounds were shown to compete with the BRCA2-derived Ac-FHTA-NH2 peptide and the self-association peptide of RAD51, but they had no effect on ATP binding. This study is the first reported elaboration of small-molecular-weight fragments against this challenging target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Targeting of Fumarate Hydratase from Mycobacterium tuberculosis Using Allosteric Inhibitors with a Dimeric-Binding Mode

Andrew J. Whitehouse, M. Daben J. Libardo, Monica Kasbekar, Paul D. Brear, Gerhard Fischer, Craig J. Thomas, Clifton E. Barry, Helena I. M. Boshoff, Anthony G. Coyne, Chris Abell

JOURNAL OF MEDICINAL CHEMISTRY (2019)

Article Chemistry, Medicinal

Covalent inactivation of Mycobacterium thermoresistibile inosine-5′-monophosphate dehydrogenase (IMPDH)

Ana Trapero, Angela Pacitto, Daniel Shiu-Hin Chan, Chris Abell, Tom L. Blundell, David B. Ascher, Anthony G. Coyne

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)

Article Chemistry, Medicinal

Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors

Mohamad Sabbah, Vitor Mendes, Robert G. Vistal, David M. G. Dias, Monika Zahorszka, Katarina Mikusova, Jana Kordulakova, Anthony G. Coyne, Tom L. Blundell, Chris Abell

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Correction Chemistry, Medicinal

Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors (vol 63, pg 4749, 2020)

Mohamad Sabbah, Vitor Mendes, Robert G. Vistal, David M. G. Dias, Monika Zahorszka, Katarina Mikusova, Jana Kordulakova, Anthony G. Coyne, Tom L. Blundell, Chris Abell

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Biochemistry & Molecular Biology

Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification

Sherine E. Thomas, Andrew J. Whitehouse, Karen Brown, Sophie Burbaud, Juan M. Belardinelli, Jasper Sangen, Ramanuj Lahiri, Mark Daben J. Libardo, Pooja Gupta, Sony Malhotra, Helena I. M. Boshoff, Mary Jackson, Chris Abell, Anthony G. Coyne, Tom L. Blundell, Rodrigo Andres Floto, Vitor Mendes

NUCLEIC ACIDS RESEARCH (2020)

Article Chemistry, Medicinal

Systematic Investigation of the Permeability of Androgen Receptor PROTACs

Duncan E. Scott, Timothy P. C. Rooney, Elliott D. Bayle, Tashfina Mirza, Henriette M. G. Willems, Jonathan H. Clarke, Stephen P. Andrews, John Skidmore

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Article Chemistry, Medicinal

Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis

Joao A. Ribeiro, Alexander Hammer, Gerardo A. Libreros-Zuniga, Sair M. Chavez-Pacheco, Petros Tyrakis, Gabriel S. de Oliveira, Timothy Kirkman, Jamal El Bakali, Silvana A. Rocco, Mauricio L. Sforca, Roberto Parise-Filho, Anthony G. Coyne, Tom L. Blundell, Chris Abell, Marcio V. B. Dias

ACS INFECTIOUS DISEASES (2020)

Article Multidisciplinary Sciences

Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site

Vitor Mendes, Simon R. Green, Joanna C. Evans, Jeannine Hess, Michal Blaszczyk, Christina Spry, Owain Bryant, James Cory-Wright, Daniel S-H Chan, Pedro H. M. Torres, Zhe Wang, Navid Nahiyaan, Sandra O'Neill, Sebastian Damerow, John Post, Tracy Bayliss, Sasha L. Lynch, Anthony G. Coyne, Peter C. Ray, Chris Abell, Kyu Y. Rhee, Helena I. M. Boshoff, Clifton E. Barry, Valerie Mizrahi, Paul G. Wyatt, Tom L. Blundell

Summary: Coenzyme A (CoA) is a crucial factor in various metabolic pathways and cellular processes, particularly in prokaryotes such as Mycobacterium tuberculosis. The biosynthesis of CoA involves five steps, with the second and third steps catalyzed by a bifunctional protein CoaBC in most prokaryotes. The researchers identified inhibitors of M. tuberculosis CoaB through a high-throughput screen and discovered a cryptic allosteric binding site within the enzyme.

NATURE COMMUNICATIONS (2021)

Article Chemistry, Medicinal

Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-L-cysteine Synthetase (CoaB) Activity

Joanna C. Evans, Dinakaran Murugesan, John M. Post, Vitor Mendes, Zhe Wang, Navid Nahiyaan, Sasha L. Lynch, Stephen Thompson, Simon R. Green, Peter C. Ray, Jeannine Hess, Christina Spry, Anthony G. Coyne, Chris Abell, Helena I. M. Boshoff, Paul G. Wyatt, Kyu Y. Rhee, Tom L. Blundell, Clifton E. I. I. I. I. I. I. Barry, Valerie Mizrahi

Summary: Coenzyme A (CoA) is an essential cofactor in all living cells, and the pathway to CoA biosynthesis is considered a potential source of novel tuberculosis drug targets. This study identified a small molecule inhibitor, compound 1f, that displays on-target activity against Mtb CoaBC, confirming the druggability of this target. Metabolomic profiling following exposure to compound 1f in wild-type Mtb H37Rv produced a signature consistent with perturbations in pantothenate and CoA biosynthesis.

ACS INFECTIOUS DISEASES (2021)

Article Chemistry, Medicinal

Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode

Helen K. Boffey, Timothy P. C. Rooney, Henriette M. G. Willems, Simon Edwards, Christopher Green, Tina Howard, Derek Ogg, Tamara Romero, Duncan E. Scott, David Winpenny, James Duce, John Skidmore, Jonathan H. Clarke, Stephen P. Andrews

Summary: Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are promising therapeutic targets in diseases such as cancer, immunological disorders, and neurodegeneration. In this study, the physicochemical properties of a selective PI5P4K gamma inhibitor were improved, enabling its interaction with PI5P4K gamma in intact cells without inhibiting PI5P4K alpha or PI5P4K beta. The X-ray structure of PI5P4K gamma bound to an inhibitor revealed an allosteric binding mode.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biophysics

Microfluidic preparation of composite hydrogel microparticles for the staining of microalgal cells*

Tina Leontidou, Ziyi Yu, Jeannine Hess, Katrin Geisler, Alison G. Smith, Anthony Coyne, Chris Abell

Summary: We demonstrate the generation of novel composite hydrogel microparticles loaded with BODIPY 505/515, which can be used to deliver the dye to microalgal cells to stain the intracellular lipids. The microparticles were prepared by combining polymeric micelles with hydrogel technology to obtain microparticles of enhanced loading capacity. The method can also be used to stain other types of microalgal cells.

COLLOIDS AND SURFACES B-BIOINTERFACES (2023)

Article Chemistry, Multidisciplinary

Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference

Jamal El Bakali, Michal Blaszczyk, Joanna C. Evans, Jennifer A. Boland, William J. McCarthy, Imam Fathoni, Marcio V. B. Dias, Eachan O. Johnson, Anthony G. Coyne, Valerie Mizrahi, Tom L. Blundell, Chris Abell, Christina Spry

Summary: By performing a fragment screen, we identified three series of fragments that occupy distinct regions in the active site of MtbPPAT. Guided by X-ray crystal structures, we successfully linked weakly-binding fragments to produce an active site binder with Mtb activity, as demonstrated by CRISPR interference. This study represents a significant progress in validating MtbPPAT as a potential drug target and designing anti-TB drugs targeting MtbPPAT.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2023)

Review Biochemistry & Molecular Biology

Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections

William Addison, Martyn Frederickson, Anthony G. Coyne, Chris Abell

Summary: This article focuses on recent research on potential therapeutic targets for Mab infections and discusses various approaches used to discover small molecule inhibitors.

RSC MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death

Duncan E. Scott, Nicola J. Francis-Newton, May E. Marsh, Anthony G. Coyne, Gerhard Fischer, Tommaso Moschetti, Andrew R. Bayly, Timothy D. Sharpe, Kalina T. Haas, Lorraine Barber, Chiara R. Valenzano, Rajavel Srinivasan, David J. Huggins, Miyoung Lee, Amy Emery, Bryn Hardwick, Matthias Ehebauer, Claudio Dagostin, Alessandro Esposito, Luca Pellegrini, Trevor Perrior, Grahame McKenzie, Tom L. Blundell, Marko Hyvonen, John Skidmore, Ashok R. Venkitaraman, Chris Abell

Summary: The study identifies CAM833 as an orthosteric inhibitor of RAD51:BRC, which affects DNA repair and potentiates cell death induced by DNA damage, working in coordination with PARP1 inhibitors to suppress growth in BRCA2-wildtype cells.

CELL CHEMICAL BIOLOGY (2021)

暂无数据